We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo

By LabMedica International staff writers
Posted on 29 Sep 2021

Visby Medical (San Jose, CA, USA) presented its new portable PCR COVID-19 test kit at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. More...

AACC's annual meeting which was held this year in Atlanta on September 26-30 is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries. Visby has become the first company to be granted FDA EUA for a portable PCR COVID-19 test kit, which it has named Personal PCR. Since the last seven years, Adam de la Zerda, the founder and CEO of Visby, has been working on shrinking the traditional PCR testing machine which is the size of a large microwave to a portable size that would fit in the palm. By bringing the power of the lab in the palm of the hand, the portable Personal PCR has the potential to be used by anyone, anywhere.

A sample taken via a nasal swab is inserted into the kit which features LED lights that indicate the test is running and alerts when it is completed. Visby’s portable Personal PCR test goes anywhere to deliver the serious infection result needed in less than 30 minutes. The single-use test with less than two minutes of hands-on time is easy to use, and delivers fast and accurate result right at the point of need. Visby’s Personal PCR is currently limited to lab use, although the company’s ultimate goal is to make the test available over the counter to anyone, anywhere at an affordable price.

Related Links:
Visby Medical 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.